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Rationale: The current hypothesis that human pulmonary alveolari-
zation is complete by 3 years is contradicted by new evidence of
alveolarization throughout adolescence in mammals.
Objectives: We reexamined the current hypothesis using helium-3
(3He)magnetic resonance (MR) to assess alveolar size noninvasively
between 7 and 21 years, during which lung volume nearly quadru-
ples. If new alveolarization does not occur, alveolar size should in-
crease to the same extent.
Methods: Lung volumes were measured by spirometry and plethys-
mography in 109 healthy subjects aged 7–21 years. Using 3HeMR we
determined two independentmeasures ofperipheral airspacedimen-
sions:apparentdiffusioncoefficient(ADC)of3HeatFRC(n¼109),and
average diffusion distance of helium ðXrmsÞ by q-space analysis (n ¼
46). We compared the change in these parameters with lung growth
against a model of lung expansion with no new alveolarization.
Measurements andMain Results: ADC increased by 0.19% for every
1% increment in FRC (95% confidence interval [CI], 0.13–0.25),
whereas the expected change in the absence of neoalveolarization
is 0.41% (95% CI, 0.31–0.52). Similarly, increase of ðXrmsÞ with FRC
was significantly less than the predicted increase in the absence of
neoalveolarization. The number of alveoli is estimated to increase
1.94-fold (95% CI, 1.64–2.30) across the age range studied.
Conclusions: Our observations are best explained by postulating that
the lungsgrowpartlybyneoalveolarization throughout childhoodand
adolescence. This has important implications: developing lungs have
thepotential to recover fromearly life insults and respond toemerging
alveolar therapies.Conversely,drugs,diseases,orenvironmentalexpo-
sures could adversely affect alveolarization throughout childhood.
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The process and timing of postnatal development of alveoli
(alveolarization) in the human lung is poorly understood (1,
2) despite a number of studies in recent decades (3, 4). Apart
from clarifying the prognosis of diseases of early childhood,
accurate knowledge of alveolarization can contribute to under-
standing the factors affecting lung growth and development and
lung structure–function relationships. Further, it can provide
the basis for the development and evaluation of new treatment
modalities designed to restore damaged alveolar function.
Currently, pulmonary alveoli are thought to stop multiply-
ing by 2–3 years of age in humans (5, 6), although some have
suggested 7–8 years as the limit (7, 8). This hypothesis is based
on studies using older morphometric histologic techniques to
analyze whole lungs from autopsies of children. However,
there is a disparity between these studies both in the measured
alveolar number and in the estimated age at which alveolari-
zation is complete (Figure 1) (3, 4, 7–10). Repeating these
studies with modern techniques of morphometry is impractical
because of severe ethical constraints in access to adequate
specimens from children (11). However, new evidence based
on modern techniques has shown that alveolarization contin-
ues beyond early life and through maturity in some mammals
(12–14). Post-pneumonectomy alveolarization can occur in
mature animals (13). Although there is increasing acceptance
of the possibility of late alveolarization in humans (1), there is
no direct evidence for this.
In vivomeasurement methods are currently the only realistic
options to study human alveolarization. One such novel method
depends on the measurement of self-diffusion of hyperpolarized
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
It is believed that human pulmonary alveolarization ceases
in early childhood and that new alveoli do not form after
about 2–3 years of life.
What This Study Adds to the Field
We provide direct evidence that supports ongoing alveola-
rization throughout childhood and adolescence in humans.
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helium-3 (3He) in the lung periphery during a brief breath-hold
using magnetic resonance (MR). A parameter known as appar-
ent diffusion coefficient (ADC) can be determined, which is
related to the dimensions of the enclosing structure, in this case
the lung peripheral airspaces including alveolar ducts and
alveoli (15, 16). Recently, it has also become possible to deter-
mine the average linear dimensions of the peripheral airspaces
and alveoli by 3HeMR (17).
Using 3HeMR, we tested the hypothesis that human alveola-
rization stops by 3 years of age. Because human lung volume
increases three- to fourfold between 7 years of age and adult-
hood (18), the volume of individual alveoli should increase to
the same extent over this period of growth if no more alveoli
form. 3HeMR can reliably detect such an increase in alveolar
size. Some of the results of these studies have been previously
reported in the form of an abstract (19).
METHODS
Subjects
Children and young adults (7–21 yr of age) were recruited from the
Leicester respiratory cohorts (20) and a community database. Of the
173 who attended, we excluded 53 born before 36 weeks of gestation,
admitted to a neonatal unit or with significant respiratory illnesses, and
11 because data did not meet validity criteria, leaving 109 subjects. The
study had Research Ethics Committee approval. Written informed
consent was obtained from all subjects and, for minors less than 18
years, from their parents or legal guardians.
Physiologic Measurements
We measured height, weight, and at least three technically acceptable
recordings of spirometry and plethysmography (Jaeger Masterscreen
Body, Wuerzburg, Germany) and recorded the highest values of
FEV1 and FVC and the mean value of FRC (21, 22). Z-scores for
height and weight (23) and spirometry and plethysmography (18, 24)
were based on United Kingdom reference values.
Hyperpolarized 3HeMR
3HeMR was undertaken in a 0.15-T permanent magnet system (Inter-
magnetics General Corp., New York, NY), where the subjects lie su-
pine and breath-hold after inhalation of 600 ml of a mixture of 3He in
4He from FRC. We used two techniques of MR.
First, we obtained the global ADC using a modified rapid acquisition
with refocused echoes MR sequence (25). At least three technically
satisfactory ADC values were obtained in all subjects and the mean
was taken as the raw ADC. Separate measurements done with constant
bolus volume but different concentrations of helium were used to adjust
the raw ADC for differences in 3He concentration: the concentration-
corrected value is ADC0. We also conducted measurements with differ-
ent bolus sizes in volunteers (bolus effect study) to determine the effect
of lung inflation on ADC.
The second technique (q-space technique) (17) was used in 46 sub-
jects. The mean displacement ðXrmsÞ of 3He atoms is derived from the
displacement probability profile of the 3He atoms obtained from this
technique. This gives a direct measure of mean linear dimensions of
peripheral airspaces. We also applied the Yablonskiy acinar model (26)
to the q-space data and obtained values for mean alveolar duct
diameter, R (including alveolar sleeve), and mean alveolar sleeve
depth, h. The effect of helium concentration and bolus size on these
parameters was estimated.
Statistical Analysis
We fitted a multilevel linear regression model of log-transformedADC0
against log-transformed FRC and relative inflation volume combining
the data from single measurements from the main study with measure-
ments at varying bolus volumes from the bolus effect study. The first
level of the model represents subjects and the second level different
measurements on a given subject. The null hypothesis of no neoalveo-
larization is satisfied if the regression slopes of ADC against FRC and
inflation volume are equal. We tested this using the Wald test.
The model was also used to estimate the fully concentration- and
volume-corrected ADC: ADCcorr. We assessed associations of log-
transformed ADCcorr with age, height, weight, and log FRC separately
using linear regression models with and without adjusting for con-
founding factors. All tests were two-sided with a significance threshold
of 0.05. Similarly, we tested for trends in mean peripheral airspace
dimension with height, weight, age, and FRC. For this outcome, we
did not adjust for potential confounding because of limited sample size.
Data were analyzed using Stata Version 11 (StataCorp, College Sta-
tion, TX). Details of methods are provided in the online supplement.
RESULTS
Demographics and Potential Confounders
The study population consisted of 109 subjects (50 males) aged
7–21 years (median, 12.8 yr): 79 (72.4%) whites; 22 (20.2%) of
south Asian origin; and 8 (7.3%) of other or mixed ethnicity.
Forty six participants (42.2%) had current or previous passive
exposure to tobacco smoke (before birth or during childhood).
Seven (6.4%) had tried cigarette smoking but none were cur-
rent smokers. Previous inhaled corticosteroid treatment was
recorded in 18 (16.5%).
Physiologic and Lung Function Measurements
All subjects were appropriately grown (Table 1) and measure-
ments of FEV1, FVC, and FRC (Table 1) were approximately
normally distributed. The range of the measured parameters
was as expected given the wide age range. Linear regression
of FRC on age gave a 3.4-fold increase in mean estimated
FRC from 7 (1.02 L) to 21 years (3.50 L).
Hyperpolarized 3HeMR
Within-subject values of ADC were internally consistent (mean
coefficient of variation, 3.1%). The concentration-corrected
Figure 1. Number of alveoli in the developing human lung estimated
by morphometry from previously published studies. Dotted lines (7 yr
and 21 yr) represent the age range reported in the present study.
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ADC (ADC0) increased by 0.19% (95% confidence interval
[CI], 0.13–0.25) for every 1% increment in FRC in the study
population (slope a) but by 0.41% (95% CI, 0.31–0.52) for
every 1% inflation in the bolus-effect study (slope b) (P value
for difference between a and b , 0.001). The change of ADC0
with FRC remained less than in the predicted scenario of “no
alveolarization” after adjusting for confounders (P ¼ 0.02).
From a and b, the rate of neoalveolarization was estimated as
0.54 (95% CI, 0.41–0.68). Based on these results, we estimated
that the observed 3.4-fold increase in FRC between 7 and 21
years of age was accompanied by a 1.94-fold (95% CI, 1.64–
2.30) increase in alveolar number and a 1.75-fold (95% CI,
1.48–2.07) increase in alveolar volume (see online supplement
for derivation).
The slope b was used to calculate ADCcorr, the fully con-
centration- and volume-corrected ADC. Mean (SD) ADCcorr
by 3HeMR was 0.094 (0.012) cm2s21, and was similar in males
and females (P ¼ 0.90). ADCcorr increased significantly with
most measures of growth including age (slope of log[ADCcorr]
vs. age ¼ 0.013; 95% CI, 0.006–0.021; r2 ¼ 0.10; P , 0.001)
(Figure 2, top panel); FRC (slope of log[ADCcorr] vs. log
[FRC] ¼ 0.16; 95% CI, 0.09–0.23; r2 ¼ 0.18; P , 0.001) (Figure
2, bottom panel); and height (slope of log[ADCcorr] vs. height ¼
0.0031; 95% CI, 0.0016–0.0047; r2 ¼ 0.13; P , 0.001). Adjust-
ment for potential confounders had negligible effects on the
measured relationships between ADC with age or FRC.
The mean peripheral airspace dimension ðXrms; range and
mean reported in Table 1) did not change with helium concen-
tration. There was no significant increase with age (slope of
logðXrmsÞ vs. age ¼ 0.005; 95% CI, 20.003 to 0.012; r2 ¼ 0.04;
P ¼ 0.2) (Figure 3, top panel) and with FRC (slope of logðXrmsÞ
vs. log[FRC] ¼ 0.053; 95% CI, 20.021 to 0.128; r2 ¼ 0.05; P ¼
0.16) (Figure 3, bottom panel). Because measurements of Xrms
with different bolus sizes changed as the cubic root of volume,
in the absence of neoalveolarization the slope of logðXrmsÞ
against log(FRC) should be 0.33. Xrms data are compatible with
an even higher rate of alveolarization than estimated from
ADC data (see online supplement and Figure 3, bottom panel).
Similarly, both parameters derived from the Yablonskiy acinar
model, R and h, changed significantly less with increasing FRC
(slope of log[R] vs. log[FRC] ¼ 0.105; 95% CI, 20.03 to 0.18;
r2 ¼ 0.159; P ¼ 0.006) (slope of log[h] vs. log[FRC] ¼ 0.16; 95%
CI, 20.013 to 0.30; r2 ¼ 0.09; P ¼ 0.03) than expected from the
scenario of no new alveolarization. These results did not alter
after adjusting for potential confounders.
DISCUSSION
We have shown that dimensions of alveoli determined by
3HeMR increase with age and lung size during childhood and
adolescence at a rate much less than would be expected if lung
growth occurred only by expansion of the preexisting airspaces.
This is best explained by postulating that lung grows largely by
neoalveolarization through childhood and adolescence. This
contradicts the prevailing hypothesis that alveolarization is re-
stricted to fetal life and early childhood. If confirmed by future
studies, our findings have important clinical implications for the
prognosis of lung disease and for the impact of drugs and envi-
ronmental exposures during childhood.
The reliability of the 3HeMR technique is critical to this inter-
pretation. Our measurements were highly repeatable, with a
within-subject coefficient of variation of ADC of 3.1%. The val-
idity of ADC as a measure of pulmonary alveolar dimensions has
been demonstrated by morphometry in animal models (27, 28) and
in human lungs (29, 30). These studies demonstrate the use of
ADC in noninvasively assessing peripheral airspace dimensions.
Parameters derived from the second technique of MR (R and h)
have also been validated against human lung morphometry (30).
We considered the possibility that our results could be ex-
plained by changes in geometry of lung acinus with growth rather
than neoalveolarization. However, our q-space data, analyzed us-
ing the acinar model of Yablonskiy and coworkers (26), show that
both alveolar sleeve diameter and alveolar duct diameter in-
creased less than expected with lung growth. In addition, because
ADC and the parameters derived from q-space MR are mea-
sured with diffusion times of 14 and 5 milliseconds, respectively,
they measure different geometric aspects of the peripheral air-
spaces and changes in relative geometry should be reflected in
different relationships of these parameters with growth. How-
ever, both increase with FRC at a rate considerably slower than
expected in the absence of neoalveolarization. Therefore, it is
unlikely that changes in geometry occur with growth.
In the only other report of ADC in childhood, Altes and
coworkers (31) measured ADC in 29 healthy subjects ranging
from 4–30 years. They also report an increase of ADC with
age. However, they did not measure lung size by independent
TABLE 1. MEAN AND DISTRIBUTION OF MEASUREMENTS INCLUDING LUNG FUNCTION TESTS AND
HELIUM MAGNETIC RESONANCE DATA
Measurement N* Mean (SD) Range
Anthropometry
Height, cm 109 154.7 (14.9) 122.6 to 184.5
Weight, kg 109 49.7 (14.8) 22.5 to 99.7
Lung function
FEV1, L 108 2.8 (0.89) 1.34 to 5.16
FVC, L 108 3.2 (1.02) 1.51 to 5.85
FRC, L 109 1.98 (0.7) 1.02 to 3.95
FEV1 z-score 108 0.2 (0.94) 22.5 to 2.9
FVC z-score 108 0.09 (1.00) 22.4 to 2.6
FRC z-score 109 20.55 (0.95) 23.2 to 1.9
3HeMR data
ADCcorr, cm
2sec21 109 0.094 (0.012) 0.070 to 0.139
Xrms , mm 45
† 0.418 (0.039) 0.354 to 0.515
Alveolar duct radius including alveolar sleeve (R)‡, mm 46† 0.426 (0.040) 0.318 to 0.503
Alveolar sleeve height (h)‡, mm 46† 0.244 (0.043) 0.164 to 0.345
Definition of abbreviations: ADC ¼ apparent diffusion coefficient of 3He; Xrms ¼ mean peripheral airspace diameter.
*Number of technically acceptable observations.
yMeasurements were done only in a subset of the volunteers.
zAlveolar duct radius (R) and alveolar sleeve height (h) derived from application of the Yablonskiy model of alveolar duct (26).
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means and there was no attempt to determine an expected line
for increase of ADC with age. Shanbhag and coworkers (17)
measured Xrms in five children aged 6 years and in adults and
found that Xrms was lower in children than adults. There was no
assessment of lung volume in this study. The mean age of adult
subjects was 49 years, when effects of alveolar enlargement
caused by senescence (25, 32) may have begun. In support of
this, Xrms reported for the five children was very close to the
values in the two youngest adults (both 28 yr) in their study.
The belief that alveolarization in humans was complete by 3
years was based on studies using older methods of morphometry,
the drawbacks of which have been discussed previously (33).
New methods of measuring alveolar number and size have since
been developed (34, 35). However, human alveolarization has
not yet been studied using these new techniques, largely be-
cause of ethical constraints that preclude the acquisition of suit-
able postmortem lung tissue.
Recent studies in mammals using new morphometric techni-
ques support continued alveolarization to adulthood in rabbits
(14), rhesus monkeys (12), and after pneumonectomy in mature
dogs (13). Massaro and coworkers (36) showed evidence of cal-
orie intake-related alveolar gain in adult mice refed after starva-
tion. Schittny and coworkers (37) observed an increase in
alveolar number after completion of microvascular maturation
in rats using design-based stereology. Using three-dimensional
synchrotron radiation X-ray tomography, they showed local du-
plication of single capillary layers in areas of postmaturity septal
growth, which indicated a potential mechanism for postmature
alveolarization. This dispelled the notion that the immature dou-
ble capillary layer in alveolar walls is a prerequisite for new
septation. Thus, there is emerging evidence of alveolarization in
maturing lungs in other mammals. There is indirect evidence that
Figure 3. Scatterplot of mean peripheral airspace dimension Xrms
against (top panel) age and (bottom panel) FRC. The red lines indicate
back transformed log–linear fits in the top panel and log–log fits in the
bottom panel. Dotted red lines in the bottom panel indicate 95% confi-
dence intervals. Green lines in the bottom panel indicate the following in
a child with an initial FRC of 1 L: top line, predicted change in Xrms with
FRC if lung growth was accomplished only by expansion of preexisting
alveoli (scenario of no alveolarization); middle line, predicted change if
rate of neoalveolarization was 0.54 (predicted from apparent diffusion
coefficient vs. FRC multilevel model); lower line, predicted change if all
growth of lung was by neoalveolarization. The data suggest that the rate
of neoalveolarization may be even higher than predicted from the ap-
parent diffusion coefficient versus FRC model (Figure 2, bottom panel).
Figure 2. Scatterplot of apparent diffusion coefficient (ADC)0 against
(top panel) age and (bottom panel) resting lung volume (FRC). Values
are weighted mean ADC from three measurements in each individual
child and corrected to zero helium (He) concentration (ADC0) and FRC.
The solid red lines indicate back-transformed linear fits of log(ADC) on
(top panel) age and on (bottom panel) log(FRC) and the areas between
the dotted red lines are 95% simultaneous confidence bands (Scheffe
method). The green curve in the bottom panel shows the estimated
change in ADC for a child with an initial FRC of 1 L assuming that
the growth of the lung occurs only by proportional enlargement of
preexisting alveoli without new alveolarization. This curve was esti-
mated from the multilevel model (see METHODS).
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this also happens in humans. Brown and coworkers (38) used
electrical impedance tomography to determine an average alveolar
number of 90 million at age 2–3 years compared with 300 million in
adults, implying that alveolarization continues to take place after
3 years of age. Using a new unbiased morphometric technique,
Ochs and coworkers (35) showed that alveolar number was closely
related to adult lung volume and that mean alveolar size was
almost constant between subjects. If alveolarization were com-
pleted by 2–3 years, the final number of alveoli, and by extrapo-
lation the final size of the lung, would have to be set by then, which
is implausible. This provides more indirect evidence in favor of
human alveolarization beyond early childhood.
The strengths of the study include the large number of vol-
unteers from a wide age range spanning most of the period of
lung growth. Prospectively collected data on early life expo-
sures and preexisting lung disease were available (20), which
allowed selection of volunteers known to be healthy. Repeated
MR measurements at varying inflation volumes were per-
formed in some subjects, which facilitated the statistical test
of the hypothesis of no new alveolarization. Independent mea-
surement of lung size by plethysmography enabled the calcu-
lation of expected slope in the models. Finally, the application
of two different techniques of MR permitted evaluation of
lung geometry.
Studies of alveolar size and number in subjects at different
ages, including our own, share the common assumption that the
cross-sectional data are representative of longitudinal changes.
We found wide interindividual variability in ADC, but our large
number of volunteers and the repeatability of ADC measure-
ments (within subjects) minimize the effect of this problem. Also,
preliminary longitudinal data (not shown) corroborate the evi-
dence from this study. Further longitudinal measurements of
ADC will help refine the results of this study and begin to explain
the wide population scatter of ADC values. The assumptions un-
derpinning the multilevel regression model are transparent and
the model fits the data well, suggesting that the assumptions
are realistic (see online supplement).
There are important implications to our observation that
alveolarization is not confined to early life. Children who die af-
ter extremely preterm birth have been shown to have larger, sim-
pler, and fewer alveoli (39), based on histologic studies of fatal
cases. There have been no studies of alveolarization in survivors
of neonatal chronic lung disease and it is possible that there is
catch-up alveolarization. There may be hope of recovery from
diseases that result in diminished alveolar number at birth (e.g.,
pulmonary hypoplasia caused by severe oligohydramnios or
congenital diaphragmatic hernia) or later in life (e.g., surgical
lung resection). Adverse environmental exposures can affect
alveolar structure. Systemic corticosteroids in early postnatal
life can inhibit alveolarization (40, 41). If alveolarization is
not confined to early life, it is a possible that inhaled cortico-
steroids may be deleterious throughout childhood. Passive to-
bacco smoke exposure in childhood is linked to adult chronic
obstructive pulmonary disease (42). Impaired alveolarization
may be a potential mechanism linking passive smoking during
childhood to increased lung senescence and emphysema, and
therefore chronic obstructive pulmonary disease. Finally, the
advent of potential “alveolar therapy” to restore damaged al-
veolar structure (43) requires safe, noninvasive repeatable
measurements to study the outcome of future therapeutic trials.
Hyperpolarized 3HeMR provides such a method.
We conclude that there is evidence for continuing alveolari-
zation through childhood and adolescence in humans. The excit-
ing possibility of late alveolarization implies that the lung may be
able to recover from damage occurring in early life. Emerging
therapies have the potential to enhance this process. Conversely,
environmental exposures during childhood could have a longer
window of opportunity to impair the process of alveolariza-
tion, with potential adverse consequences throughout later
life.
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